Welcome to the Rare Mutations Patient Gateway Newsletter for March 2023. These articles highlight the advances we are making to identify the underlying molecular causes of NSCLC. This progress leads to biomarkers and targeted therapies and contributes to the gains we are starting to see in lung cancer survivorship. These improvements also underscore the importance of comprehensive biomarker testing to inform treatment decisions and shared decision-making. Unfortunately, we know that not all patients have access to this critical testing and may not receive appropriate treatment as a result. Research NewsPharmacy Times BioPharma Dive Pharmacy Times Targeted Oncology NewsBeezer MDPI Have You Seen?
More Resources for Patient & Caregivers
If you need further assistance, please email us at support@lungevity.org. Our team is always here to assist you. |